The estimated Net Worth of Charles M Watts is at least $738 Thousand dollars as of 16 July 2024. Charles Watts owns over 26,368 units of Accelerate Diagnostics Inc stock worth over $603,781 and over the last 7 years he sold AXDX stock worth over $0. In addition, he makes $133,904 as Independent Director at Accelerate Diagnostics Inc.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Charles Watts AXDX stock SEC Form 4 insiders trading
Charles has made over 7 trades of the Accelerate Diagnostics Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently he exercised 26,368 units of AXDX stock worth $42,452 on 16 July 2024.
The largest trade he's ever made was exercising 150,711 units of Accelerate Diagnostics Inc stock on 31 March 2023 worth over $242,645. On average, Charles trades about 20,585 units every 65 days since 2017. As of 16 July 2024 he still owns at least 375,019 units of Accelerate Diagnostics Inc stock.
You can see the complete history of Charles Watts stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Charles Watts biography
Dr. Charles McDonald Watts M.D. serves as Independent Director of the Company. Until his retirement, Dr. Watts served as Chief Medical Officer at Northwestern Memorial Hospital (NMH) and Associate Dean for Clinical Affairs at the Feinberg School of Medicine, Northwestern University from 2001 to 2011. Prior to his tenure at Northwestern, Dr. Watts served as Chief of Clinical Affairs and Associate Dean at the University of Michigan Medical Center. He has also served as Executive in Residence for the Health Management Academy, as an active faculty member of a nationally based Physician Leadership Program. Dr. Watts has served as a Director of Providence Health and Services (Seattle, Washington) from 2012 to 2016 where he chaired the Quality and Patient Safety Improvement Committee, and recently served as a Trustee of Swedish Health Services, Inc. until June of this year. He currently serves as a Trustee on the Institute for Systems Biology Board (Seattle, Washington). He received his undergraduate and medical degrees from the University of Michigan.
What is the salary of Charles Watts?
As the Independent Director of Accelerate Diagnostics Inc, the total compensation of Charles Watts at Accelerate Diagnostics Inc is $133,904. There are 8 executives at Accelerate Diagnostics Inc getting paid more, with John Phillips having the highest compensation of $12,300,900.
How old is Charles Watts?
Charles Watts is 77, he's been the Independent Director of Accelerate Diagnostics Inc since 2017. There are 1 older and 13 younger executives at Accelerate Diagnostics Inc. The oldest executive at Accelerate Diagnostics Inc is Jack Schuler, 79, who is the Independent Director.
What's Charles Watts's mailing address?
Charles's mailing address filed with the SEC is 919 WEST DILLON RD, , LOUISVILLE, CO, 80027.
Insiders trading at Accelerate Diagnostics Inc
Over the last 12 years, insiders at Accelerate Diagnostics Inc have traded over $26,833,308 worth of Accelerate Diagnostics Inc stock and bought 16,366,880 units worth $209,384,489 . The most active insiders traders include Jack W Schuler, Larry N Feinberg, and Matthew Strobeck. On average, Accelerate Diagnostics Inc executives and independent directors trade stock every 16 days with the average trade being worth of $132,645. The most recent stock trade was executed by Hany Massarany on 28 June 2024, trading 4,737 units of AXDX stock currently worth $7,627.
What does Accelerate Diagnostics Inc do?
accelerate diagnostics, inc. (nasdaq:axdx), is an in vitro diagnostics company focused on developing and commercializing innovative systems for the rapid identification and antimicrobial susceptibility testing of infectious pathogens. the company's revolutionary id/ast platform utilizes a proprietary process with both genomic and phenotypic detection technologies that significantly decreases time to result while achieving high sensitivity and specificity. in addition to the id/ast development pipeline, the company also owns and licenses its proprietary optichem™ surface coatings technology, which has numerous applications for binding in bio-analytical systems, such as microarrays.
What does Accelerate Diagnostics Inc's logo look like?
Complete history of Charles Watts stock trades at Accelerate Diagnostics Inc and Biodesix Inc
Accelerate Diagnostics Inc executives and stock owners
Accelerate Diagnostics Inc executives and other stock owners filed with the SEC include:
-
John Phillips,
Chief Executive Officer, Chief Operating Officer, Director -
Steve Reichling,
Chief Financial Officer -
Jack Phillips,
CEO, Pres & Director -
Ron Price,
Senior Vice President, Head of Commercial Operations, Americas -
Roland Diggelmann,
Independent Director -
Louise Francesconi,
Independent Director -
Steve Reichling,
CFO & Chief Accounting Officer -
Ron Price,
Chief Commercial Officer of Americas -
Charles Watts,
Independent Director -
Frank ten Brink,
Independent Director -
Matthew Strobeck,
Independent Director -
Jack Schuler,
Independent Director -
Mark Miller,
Independent Director -
Thomas Brown,
Independent Director -
John Patience,
Independent Chairman of the Board -
Nedal Safwat,
Chief Strategy Officer -
Dr. Lawrence Mertz,
Sr. VP and Head of R&D -
John Meduri,
Chief Strategy Officer -
Laura Costa,
Sr. VP & Head of Global Customer Support -
Cherif Bousselham,
Sr. VP & Head of Sales - EMEA -
Gretchen Strohminger,
Sr. VP and Head of HR & Culture -
Michael Bridge,
Sr. VP, Gen. Counsel & Sec. -
Laura Pierson,
Investor Relations Officer -
Larry N Feinberg,
10% owner -
Pete Bantock,
CHIEF COMMERCIAL OFFICER -
Lawrence Mehren,
PRESIDENT AND CEO -
Marran H. Ogilvie,
Director -
Jennifer Regan,
Director -
Mark S. Black,
Director -
Ventures, Llc Abeja,
10% owner -
Romney Humphries,
Chief Scientific Officer -
Larry Michael Mertz,
Chief Technology Officer -
Hany Massarany,
Director -
Jack Phillips,
Chief Executive Officer -
Wayne Burris,
Director -
David Patience,
Chief Financial Officer